482 related articles for article (PubMed ID: 17339481)
1. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression.
Herber D; Brown TP; Liang S; Young DA; Collins M; Dunussi-Joannopoulos K
J Immunol; 2007 Mar; 178(6):3822-30. PubMed ID: 17339481
[TBL] [Abstract][Full Text] [Related]
2. IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice.
Rankin AL; Guay H; Herber D; Bertino SA; Duzanski TA; Carrier Y; Keegan S; Senices M; Stedman N; Ryan M; Bloom L; Medley Q; Collins M; Nickerson-Nutter C; Craft J; Young D; Dunussi-Joannopoulos K
J Immunol; 2012 Feb; 188(4):1656-67. PubMed ID: 22231702
[TBL] [Abstract][Full Text] [Related]
3. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
4. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival.
Mannoor K; Matejuk A; Xu Y; Beardall M; Chen C
J Immunol; 2012 Apr; 188(8):3628-38. PubMed ID: 22407922
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-21 receptor blockade inhibits secondary humoral responses and halts the progression of preestablished disease in the (NZB × NZW)F1 systemic lupus erythematosus model.
Zhang M; Yu G; Chan B; Pearson JT; Rathanaswami P; Delaney J; Ching Lim A; Babcook J; Hsu H; Gavin MA
Arthritis Rheumatol; 2015 Oct; 67(10):2723-31. PubMed ID: 26097207
[TBL] [Abstract][Full Text] [Related]
6. CTL-Promoting Effects of IL-21 Counteract Murine Lupus in the Parent→F1 Graft-versus-Host Disease Model.
Nguyen V; Rus H; Chen C; Rus V
J Immunol; 2016 Feb; 196(4):1529-40. PubMed ID: 26792801
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-9 Is Associated with Elevated Anti-Double-Stranded DNA Antibodies in Lupus-Prone Mice.
Yang J; Li Q; Yang X; Li M
Mol Med; 2015 Apr; 21(1):364-70. PubMed ID: 25902303
[TBL] [Abstract][Full Text] [Related]
8. IL-34-Dependent Intrarenal and Systemic Mechanisms Promote Lupus Nephritis in MRL-
Wada Y; Gonzalez-Sanchez HM; Weinmann-Menke J; Iwata Y; Ajay AK; Meineck M; Kelley VR
J Am Soc Nephrol; 2019 Feb; 30(2):244-259. PubMed ID: 30622154
[TBL] [Abstract][Full Text] [Related]
9. IL-33 neutralization suppresses lupus disease in lupus-prone mice.
Li P; Lin W; Zheng X
Inflammation; 2014 Jun; 37(3):824-32. PubMed ID: 24398614
[TBL] [Abstract][Full Text] [Related]
10. IL-10 regulates murine lupus.
Yin Z; Bahtiyar G; Zhang N; Liu L; Zhu P; Robert ME; McNiff J; Madaio MP; Craft J
J Immunol; 2002 Aug; 169(4):2148-55. PubMed ID: 12165544
[TBL] [Abstract][Full Text] [Related]
11. Siglec-G deficiency leads to more severe collagen-induced arthritis and earlier onset of lupus-like symptoms in MRL/lpr mice.
Bökers S; Urbat A; Daniel C; Amann K; Smith KG; Espéli M; Nitschke L
J Immunol; 2014 Apr; 192(7):2994-3002. PubMed ID: 24600033
[TBL] [Abstract][Full Text] [Related]
12. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
[TBL] [Abstract][Full Text] [Related]
13. B cell apoptosis accelerates the onset of murine lupus.
Trébéden-Nègre H; Weill B; Fournier C; Batteux F
Eur J Immunol; 2003 Jun; 33(6):1603-12. PubMed ID: 12778478
[TBL] [Abstract][Full Text] [Related]
14. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice.
Lenda DM; Stanley ER; Kelley VR
J Immunol; 2004 Oct; 173(7):4744-54. PubMed ID: 15383612
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody therapy that targets phospholipid-binding protein delays lupus activity in MRL/lpr mice.
Mihaylova N; Bradyanova S; Chipinski P; Chausheva S; Kyurkchiev D; Tchorbanov AI
Scand J Immunol; 2020 Sep; 92(3):e12915. PubMed ID: 32533866
[TBL] [Abstract][Full Text] [Related]
16. Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice.
Cai Z; Wong CK; Dong J; Chu M; Jiao D; Kam NW; Lam CW; Tam LS
Clin Exp Immunol; 2015 Aug; 181(2):253-66. PubMed ID: 25845911
[TBL] [Abstract][Full Text] [Related]
17. Murine models of systemic lupus erythematosus: B and T cell responses to spliceosomal ribonucleoproteins in MRL/Fas(lpr) and (NZB x NZW)F(1) lupus mice.
Monneaux F; Dumortier H; Steiner G; Briand JP; Muller S
Int Immunol; 2001 Sep; 13(9):1155-63. PubMed ID: 11526096
[TBL] [Abstract][Full Text] [Related]
18. T cell-derived IFN-γ downregulates protective group 2 innate lymphoid cells in murine lupus erythematosus.
Düster M; Becker M; Gnirck AC; Wunderlich M; Panzer U; Turner JE
Eur J Immunol; 2018 Aug; 48(8):1364-1375. PubMed ID: 29671873
[TBL] [Abstract][Full Text] [Related]
19. Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice.
Yan SX; Deng XM; Wang QT; Sun XJ; Wei W
Acta Pharmacol Sin; 2015 Nov; 36(11):1367-76. PubMed ID: 26456588
[TBL] [Abstract][Full Text] [Related]
20. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology.
Kikawada E; Lenda DM; Kelley VR
J Immunol; 2003 Apr; 170(7):3915-25. PubMed ID: 12646661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
